1. Home
  2. ESTA vs URGN Comparison

ESTA vs URGN Comparison

Compare ESTA & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Establishment Labs Holdings Inc.

ESTA

Establishment Labs Holdings Inc.

HOLD

Current Price

$78.00

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$47.44

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESTA
URGN
Founded
2004
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
ESTA
URGN
Price
$78.00
$47.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
7
Target Price
$86.86
$29.29
AVG Volume (30 Days)
441.4K
808.9K
Earning Date
05-06-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
42.67
N/A
EPS
N/A
N/A
Revenue
$61,208,000.00
$1,128,000.00
Revenue This Year
$28.05
$129.09
Revenue Next Year
$26.21
$70.96
P/E Ratio
N/A
N/A
Revenue Growth
76.49
N/A
52 Week Low
$33.35
$15.86
52 Week High
$97.59
$48.03

Technical Indicators

Market Signals
Indicator
ESTA
URGN
Relative Strength Index (RSI) 31.96 67.02
Support Level $63.71 $18.23
Resistance Level $83.31 N/A
Average True Range (ATR) 4.47 2.41
MACD -1.34 0.07
Stochastic Oscillator 2.88 78.59

Price Performance

Historical Comparison
ESTA
URGN

About ESTA Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: